Combining Guanfacine Extended-Release at Night with Vyvanse in the Morning for ADHD
Yes, taking guanfacine extended-release at night and Vyvanse (lisdexamfetamine) in the morning is an appropriate and FDA-approved combination therapy for ADHD management, particularly when stimulant monotherapy provides suboptimal symptom control.
Rationale for This Combination
The FDA label for Vyvanse explicitly recommends morning administration to avoid insomnia 1. Guanfacine extended-release (GXR) is one of only two non-stimulants with FDA approval specifically for adjunctive use with stimulants 2. This combination addresses ADHD symptoms throughout the day while potentially mitigating stimulant-related side effects.
Timing of Administration: Morning vs. Evening Guanfacine
Either morning or evening dosing of guanfacine is equally effective, but evening administration may offer practical advantages:
- Equivalent efficacy: Multiple high-quality RCTs demonstrate that GXR administered morning or evening shows no significant difference in ADHD symptom reduction when combined with psychostimulants 3, 4
- Evening dosing benefits: Taking guanfacine at night may help manage the most common side effect—somnolence (occurring in 38-45% of patients)—by having peak sedation occur during sleep hours 5, 4
- All-day coverage: Both timing regimens provide consistent symptom control throughout morning, afternoon, and evening periods 6, 7
Evidence Supporting This Combination
The strongest evidence comes from a 2012 multicenter RCT (N=461) showing that GXR adjunctive to long-acting psychostimulants produced significantly greater ADHD symptom improvement compared to stimulant monotherapy, whether GXR was given morning or evening (p<0.001 for both) 3. Importantly, this combination generated no new safety signals beyond those seen with either medication alone 3.
Key Clinical Considerations
Cardiovascular Monitoring
Before initiating this combination:
- Obtain personal and family cardiac history (sudden death, arrhythmias, cardiomyopathy, long QT syndrome) 2
- Monitor blood pressure and heart rate at baseline and during treatment
- Vyvanse typically causes mild increases in HR (1-2 bpm) and BP (1-4 mmHg), while guanfacine causes mild decreases 2
- These opposing cardiovascular effects may partially offset each other
Common Side Effects
- Guanfacine: Somnolence (38.6%), headache (20.5%), fatigue (15.2%), dry mouth, dizziness 5
- Vyvanse: Decreased appetite, insomnia, abdominal pain, headache 1
- Most adverse events are mild to moderate in severity 3
Critical Safety Warning
Never abruptly discontinue guanfacine—taper gradually to avoid rebound hypertension 2. This is a black-box level concern for alpha-2 agonists.
Dosing Algorithm
- Start Vyvanse: 30 mg once daily in the morning, titrate by 10-20 mg weekly to maximum 70 mg/day 1
- If suboptimal response after 4+ weeks (ADHD-RS-IV ≥24 or CGI-Severity ≥3): Add guanfacine extended-release
- Guanfacine dosing: Start 1 mg at bedtime, titrate weekly by 1 mg to optimal response (typical range 1-4 mg, maximum 6 mg in Japan guidelines) 8, 3
- Monitor response: Assess symptom control morning, afternoon, and evening using validated scales
When This Combination Is Particularly Useful
- Stimulant monotherapy provides partial but insufficient response 3
- Comorbid oppositional symptoms (GXR adjunctive therapy significantly reduces oppositional behaviors) 9
- Stimulant side effects (insomnia, appetite suppression) limit dose escalation
- Need for extended symptom coverage into evening hours 7
Important Caveats
Cognitive effects differ: Recent 2025 data shows lisdexamfetamine significantly improves reaction time and attention variability, while guanfacine may actually worsen attention variability in some children 10. This suggests guanfacine's primary benefit in combination therapy may be behavioral regulation rather than core attention improvement—the stimulant carries the primary cognitive benefit.
Renal impairment: Reduce Vyvanse maximum dose to 50 mg/day (severe impairment) or 30 mg/day (ESRD) 1
Age considerations: Both medications are FDA-approved for ages 6+ years, though guanfacine evidence is stronger in children than adults 5, 11